• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Towards a Responsible Implementation of NIPT as a First-Tier Test in Canada: Decision-Makers' Perspectives.在加拿大将无创产前检测(NIPT)作为一线检测进行负责任的实施:决策者的观点
Prenat Diagn. 2025 Apr;45(4):453-463. doi: 10.1002/pd.6753. Epub 2025 Jan 31.
2
Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions in Average-Risk Pregnancies: A Cost-Effectiveness Analysis.非侵入性产前检测在平均风险妊娠中用于检测 21 三体、18 三体、13 三体、性染色体非整倍体和微缺失:成本效益分析。
J Obstet Gynaecol Can. 2020 Jun;42(6):740-749.e12. doi: 10.1016/j.jogc.2019.12.007. Epub 2020 Jan 31.
3
Implementing non-invasive prenatal testing in a national screening program: Lessons learned from the TRIDENT studies.在国家筛查项目中实施无创产前检测:从TRIDENT研究中吸取的经验教训。
Best Pract Res Clin Obstet Gynaecol. 2024 Dec;97:102543. doi: 10.1016/j.bpobgyn.2024.102543. Epub 2024 Sep 3.
4
Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions: A Health Technology Assessment.21三体、18三体和13三体、性染色体非整倍体及微缺失的无创产前检测:一项卫生技术评估
Ont Health Technol Assess Ser. 2019 Feb 19;19(4):1-166. eCollection 2019.
5
Limits to the scope of non-invasive prenatal testing (NIPT): an analysis of the international ethical framework for prenatal screening and an interview study with Dutch professionals.非侵入性产前检测(NIPT)的范围限制:对产前筛查国际伦理框架的分析及对荷兰专业人士的访谈研究。
BMC Pregnancy Childbirth. 2018 Oct 19;18(1):409. doi: 10.1186/s12884-018-2050-4.
6
The Emergence and Global Spread of Noninvasive Prenatal Testing.非侵入性产前检测的出现与全球传播。
Annu Rev Genomics Hum Genet. 2021 Aug 31;22:309-338. doi: 10.1146/annurev-genom-083118-015053. Epub 2021 Apr 13.
7
Disparities in integrating non-invasive prenatal testing into antenatal healthcare in Australia: a survey of healthcare professionals.澳大利亚将无创产前检测纳入产前保健中的差异:对医疗保健专业人员的调查。
BMC Pregnancy Childbirth. 2024 May 14;24(1):355. doi: 10.1186/s12884-024-06565-1.
8
Knowledge and attitudes regarding non-invasive prenatal testing among women in Saudi Arabia.沙特阿拉伯女性对无创性产前检测的知识和态度。
Prenat Diagn. 2021 Sep;41(10):1343-1350. doi: 10.1002/pd.5991. Epub 2021 Jun 27.
9
Women's preferences for NIPT as a first-line test in England and France: Challenges for genetic counseling practices.英国和法国女性对无创产前检测作为一线检测的偏好:遗传咨询实践面临的挑战。
J Genet Couns. 2024 Dec;33(6):1204-1214. doi: 10.1002/jgc4.1839. Epub 2023 Nov 16.
10
Should the scope of NIPT be limited by a 'threshold of seriousness'?无创产前检测(NIPT)的范围是否应该受到“严重程度阈值”的限制?
Eur J Hum Genet. 2025 Mar;33(2):189-193. doi: 10.1038/s41431-024-01684-x. Epub 2024 Aug 16.

本文引用的文献

1
A cross-country comparison of pregnant women's decision-making and perspectives when opting for non-invasive prenatal testing in the Netherlands and Belgium.中荷比三国孕妇选择无创性产前检测时决策与观点的跨国比较
Prenat Diagn. 2023 Mar;43(3):294-303. doi: 10.1002/pd.6329. Epub 2023 Feb 17.
2
Views of Canadian healthcare professionals on the future uses of non-invasive prenatal testing: a mixed method study.加拿大医疗保健专业人员对非侵入性产前检测未来用途的看法:一项混合方法研究。
Eur J Hum Genet. 2022 Nov;30(11):1269-1275. doi: 10.1038/s41431-022-01151-5. Epub 2022 Jul 28.
3
Clinician views and experiences of non-invasive prenatal genetic screening tests in Australia.澳大利亚临床医生对无创性产前基因筛查检测的看法和经验。
Aust N Z J Obstet Gynaecol. 2022 Dec;62(6):830-837. doi: 10.1111/ajo.13533. Epub 2022 May 10.
4
The Emergence and Global Spread of Noninvasive Prenatal Testing.非侵入性产前检测的出现与全球传播。
Annu Rev Genomics Hum Genet. 2021 Aug 31;22:309-338. doi: 10.1146/annurev-genom-083118-015053. Epub 2021 Apr 13.
5
Ethical, Legal and Social Issues (ELSI) Associated with Non-Invasive Prenatal Testing: Reflections on the Evolution of Prenatal Diagnosis and Procreative Choices.与非侵入性产前检测相关的伦理、法律和社会问题(ELSI):对产前诊断和生殖选择演变的思考。
Genes (Basel). 2021 Jan 30;12(2):204. doi: 10.3390/genes12020204.
6
Noninvasive Prenatal Testing: Views of Canadian Pregnant Women and Their Partners Regarding Pressure and Societal Concerns.非侵入性产前检测:加拿大孕妇及其伴侣对压力和社会关注的看法。
AJOB Empir Bioeth. 2021 Jan-Mar;12(1):53-62. doi: 10.1080/23294515.2020.1829173. Epub 2020 Oct 23.
7
Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226.筛查胎儿染色体异常:ACOG 实践公告,第 226 号。
Obstet Gynecol. 2020 Oct;136(4):e48-e69. doi: 10.1097/AOG.0000000000004084.
8
Rethinking counselling in prenatal screening: An ethical analysis of informed consent in the context of non-invasive prenatal testing (NIPT).反思产前筛查中的咨询:非侵入性产前检测(NIPT)背景下知情同意的伦理分析。
Bioethics. 2020 Sep;34(7):671-678. doi: 10.1111/bioe.12760. Epub 2020 Jul 4.
9
Governing the futures of non-invasive prenatal testing: An exploration of social acceptability using the Delphi method.规范非侵入性产前检测的未来:使用德尔菲法探索社会可接受性。
Soc Sci Med. 2022 Jul;304:112930. doi: 10.1016/j.socscimed.2020.112930. Epub 2020 Mar 17.
10
Implementation challenges for an ethical introduction of noninvasive prenatal testing: a qualitative study of healthcare professionals' views from Lebanon and Quebec.非侵入性产前检测引入的伦理挑战:来自黎巴嫩和魁北克的医疗保健专业人员观点的定性研究。
BMC Med Ethics. 2020 Feb 10;21(1):15. doi: 10.1186/s12910-020-0455-x.

在加拿大将无创产前检测(NIPT)作为一线检测进行负责任的实施:决策者的观点

Towards a Responsible Implementation of NIPT as a First-Tier Test in Canada: Decision-Makers' Perspectives.

作者信息

Roy Marie-Christine, Malo Marie-Françoise, Morel-Laforce Tierry, Ravitsky Vardit, Laberge Anne-Marie

机构信息

Department of Social and Preventive Medicine, School of Public Health, University of Montreal, Montreal, Canada.

Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.

出版信息

Prenat Diagn. 2025 Apr;45(4):453-463. doi: 10.1002/pd.6753. Epub 2025 Jan 31.

DOI:10.1002/pd.6753
PMID:39891168
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11987779/
Abstract

OBJECTIVE

To explore decision makers' perspectives on the conditions for a responsible implementation of non-invasive prenatal testing (NIPT) as a first-tier test in Canadian provinces' healthcare systems.

METHOD

A qualitative study was conducted with 16 Canadian decision makers who were interviewed between February 2021 and July 2022. After anonymization and transcription, interviews were coded inductively using thematic analysis.

RESULTS

Our interviews showed the complexity of the decision making environment regarding prenatal screening funding. Participants agreed that NIPT is superior to maternal serum screening as a first-tier test, but they also recognized that first-tier NIPT has limits and barriers. They described the following conditions for its responsible implementation: (1) need for time and evidence; (2) taking stakeholders' perspectives into account; (3) limit costs for the healthcare system; (4) ensure appropriate logistical conditions and harmonize the test offer; (5) ensure appropriate clinical services; (6) ensure informed consent; (7) ensure the test is presented as an individual choice to avoid eugenic concerns.

CONCLUSION

Multiple barriers and issues need to be addressed before moving NIPT from second- to first-tier. Decision makers' perspectives should be contrasted with those of other important stakeholders, including pregnant people, disability advocates and healthcare professionals.

摘要

目的

探讨决策者对于在加拿大各省医疗保健系统中将无创产前检测(NIPT)作为一线检测进行负责任实施的条件的看法。

方法

对16名加拿大决策者进行了定性研究,访谈时间为2021年2月至2022年7月。访谈进行匿名处理和转录后,采用主题分析法进行归纳编码。

结果

我们的访谈显示了产前筛查资金决策环境的复杂性。参与者一致认为,作为一线检测,NIPT优于母体血清筛查,但他们也认识到一线NIPT存在局限性和障碍。他们描述了其负责任实施的以下条件:(1)需要时间和证据;(2)考虑利益相关者的观点;(3)限制医疗保健系统的成本;(4)确保适当的后勤条件并统一检测服务;(5)确保适当的临床服务;(6)确保知情同意;(7)确保将检测作为个人选择呈现,以避免优生学方面的担忧。

结论

在将NIPT从二线检测转变为一线检测之前,需要解决多个障碍和问题。决策者的观点应与其他重要利益相关者的观点进行对比,包括孕妇、残疾权益倡导者和医疗保健专业人员。